Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.19
Views: 1012
Rating:

Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA

Prof Evan Yu speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about Cohort A of the KEYNOTE-365 study which looked at the combination of pembrolizumab plus olaparib in docetaxel-pretreated patients with metastatic castrate-resistant prostate cancer (mCRPC).

He explains that these patients were docataxel-pretreated for mCRPC and were treated with pembrolizumab IV 200mg every 3 weeks and olaparib 400mg twice daily.

Prof Yu reports that, although there was a confirmed response rate of near 12%, around half the patients had a PSA decline.

He therefore believes there is some work to do in order to understand why there is a better initial response compared with later on in the cycle.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation